Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma

International Journal of Cancer

Volumn 136, Issue 12, 2015, Pages 2761-2774

  Bernard, Sophie ^a,b,c   Danglade, Damien ^c   Gardano, Laura ^a,b   Laguillier, Christelle ^d   Lazarian, Gregory ^c   Roger, Claudine ^c   Thieblemont, Catherine ^e   Marzec, Jacek ^f   Gribben, John ^f   Cymbalista, Florence ^a,b,c   Varin Blank, Nadine ^a,b   Ledoux, Dominique ^a,b   Baran Marszak, Fanny ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c AVICENNE HOSPITAL   (France)

^d HÔPITAL JEAN VERDIER   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

B cell receptor; cytokines; Fostamatinib; Ibrutinib; mantle cell lymphoma; microenvironment; STAT3

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; FOSTAMATINIB; IBRUTINIB; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; PROTEIN KINASE SYK; RANTES; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; AGAMMAGLOBULINAEMIA TYROSINE KINASE; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; OXAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; BONE MARROW STROMA CELL; CANCER INHIBITION; CANCER SURVIVAL; CCL5 GENE; CELL ADHESION; CELL SURVIVAL; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IL 1BETA GENE; IL 6 GENE; IL 8 GENE; INHIBITION KINETICS; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA CELL; MOLECULAR INTERACTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION; AGED; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR CELL LINE; VERY ELDERLY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; FEMALE; GENE EXPRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; OXAZINES; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84927574151     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29326     Document Type: Article

References (52)

1. Swerdlow S, Campo E, Seto M, et al. Mantle cell lymphoma. In:, Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC Press, 2008. 229-232.
2. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511-18.
3. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94.
4. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 571-2.
5. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2561-2.
6. Gauld SB, Cambier JC,. Src-family kinases in B-cell development and signaling. Oncogene 2004; 23: 8001-6.
7. Pierce SK, Liu W,. The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat Rev Immunol 2010; 10: 767-77.
8. Kurosaki T, Hikida M,. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev 2009; 228: 132-48.
9. Pighi C, Gu TL, Dalai I, et al. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol (Dordr) 2011; 34: 141-53.
10. Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006; 132: 303-16.
11. Psyrri A, Papageorgiou S, Liakata E, et al. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res 2009; 15: 5724-32.
12. Boyd RS, Jukes-Jones R, Walewska R, et al. Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics 2009; 8: 1501-15.
13. Chim CS, Wong KY, Loong F, et al. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 2004; 18: 356-8.
14. Kurtova AV, Tamayo AT, Ford RJ, et al. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 2009; 113: 4604-13.
15. Medina DJ, Goodell L, Glod J, et al. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor kappaB pathways. Haematologica 2012; 97: 1255-63.
16. Quiroga MP, Balakrishnan K, Kurtova AV, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009; 114: 1029-37.
17. Buchner M, Fuchs S, Prinz G, et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009; 69: 5424-32.
18. Woyach JA, Johnson AJ, Byrd JC,. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012; 120: 1175-84.
19. Tai YT, Chang BY, Kong SY, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120: 1877-87.
20. Spaargaren M, Beuling EA, Rurup ML, et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med 2003; 198: 1539-50.
21. Herreros B, Sanchez-Aguilera A, Piris MA,. Lymphoma microenvironment: culprit or innocent? Leukemia 2008; 22: 49-58.
22. de Gorter DJ, Beuling EA, Kersseboom R, et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 2007; 26: 93-104.
23. Niedermeier M, Hennessy BT, Knight ZA, et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009; 113: 5549-57.
24. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590-4.
25. Shain KH, Tao J., The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene 2014; 33: 4107-13.
26. Young RM, Staudt LM,. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229-43.
27. Baran-Marszak F, Boukhiar M, Harel S, et al. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica 2010; 95: 1865-72.
28. Kern C, Cornuel JF, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004; 103: 679-88.
29. Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, et al. Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells. Mol Med 2011; 17: 619-27.
30. Ibrutinib approved for mantle cell lymphoma. Cancer Discov 2014; 4: OF1.
31. Chang BY, Francesco M, De Rooij MF, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013; 122: 2412-24.
32. Mocsai A, Ruland J, Tybulewicz VL,. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010; 10: 387-402.
33. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008; 111: 2230-7.
34. Pede V, Rombout A, Vermeire J, et al. Expression of ZAP70 in chronic lymphocytic leukaemia activates NF-kappaB signalling. Br J Haematol 2013; 163: 621-30.
35. Wierda WG, Johnson MM, Do KA, et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 2003; 120: 452-6.
36. Lai R, O'Brien S, Maushouri T, et al. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 2002; 95: 1071-5.
37. Giachelia M, Voso MT, Tisi MC, et al. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kappaB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2012; 53: 411-16.
38. Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, et al. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index. Arch Immunol Ther Exp (Warsz) 2010; 58: 131-41.
39. Ek S, Bjorck E, Hogerkorp CM, et al. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer 2006; 118: 2092-7.
40. Stopeck AT, Unger JM, Rimsza LM, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 2009; 50: 728-35.
41. Potti A, Ganti AK, Kargas S, et al. Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res 2002; 22: 2899-901.
42. Lee YK, Bone ND, Strege AK, et al. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004; 104: 788-94.
43. Schweighoffer E, Vanes L, Nys J, et al. The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity 2013; 38: 475-88.
44. Geiger F, Lorenz H, Xu W, et al. VEGF producing bone marrow stromal cells (BMSC) enhance vascularization and resorption of a natural coral bone substitute. Bone 2007; 41: 516-22.
45. Rougier F, Dupuis F, Denizot Y,. Human bone marrow fibroblasts-an overview of their characterization, proliferation and inflammatory mediator production. Hematol Cell Ther 1996; 38: 241-6.
46. Till KJ, Zuzel M, Cawley JC,. The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Res 1999; 59: 4419-26.
47. Sebestyen A, Kovalszky I, Mihalik R, et al. Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia. Eur J Cancer 1997; 33: 2273-7.
48. Yu YM, Wang ZH, Liu CH, et al. Ellagic acid inhibits IL-1beta-induced cell adhesion molecule expression in human umbilical vein endothelial cells. Br J Nutr 2007; 97: 692-8.
49. Uckun FM, Qazi S, Ma H, et al. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci USA 2010; 107: 2902-7.
50. Lee KG, Xu S, Wong ET, et al. Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells. J Biol Chem 2008; 283: 11189-98.
51. Kenny EF, Quinn SR, Doyle SL, et al. Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin. PLoS One 2013; 8: e74103.
52. Till KJ, Spiller DG, Harris RJ, et al. CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium. Blood 2005; 105: 4813-9.